Results 11 to 20 of about 35,812 (218)
Deciphering the enigma of neuroendocrine prostate cancer
The Journal of Clinical Investigation, 2022 Despite the clinical advances in managing metastatic prostate cancer in the last 20 years, treatments for patients with metastatic disease only offer a brief respite from disease progression, especially after first-line therapies. Research into treatment
Fatima Karzai, Ravi A. Madan
doaj +3 more sources
Neuroendocrine differentiation of prostate cancer [PDF]
Asian Journal of Andrology, 2013 Benign prostate and prostatic adenocarcinoma contain rare quiescent neuroendocrine cells while small cell neuroendocrine carcinoma (SCNC), a variant form of prostate cancer, contains highly proliferative neuroendocrine tumor cells. We provide evidence that IL-8-CXCR2-P53 pathway keeps the NE cells in a quiescent state normally. P53 mutation inactivates
Zhen, Li +7 more
openaire +2 more sources
Models of neuroendocrine prostate cancer [PDF]
Endocrine-Related Cancer, 2014 Prostate cancer remains the second leading cause of cancer death in men in the USA and most western countries. Prostatic acinar adenocarcinoma is the most commonly diagnosed form of prostate cancer. Small-cell neuroendocrine carcinoma is less frequently identified at the time of initial diagnosis, but this highly aggressive form of prostate cancer is ...
Lisa D, Berman-Booty, Karen E, Knudsen
openaire +2 more sources
Preclinical Models of Neuroendocrine Prostate Cancer
Current Protocols, 2023 AbstractProstate cancer (PCa) is the most common malignancy and the second leading cause of cancer‐related death amongst men in the United States. Neuroendocrine prostate cancer (NEPC) can either arise de novo or emerge as a consequence of therapy. De novo NEPC is rare, with an incidence of <2% of all PCa cases.
Cacciatore, Alessia +3 more
openaire +3 more sources
Neuroendocrine prostate cancer
Cancer Urology, 2023 In Russia, prostate cancer is a common disease with fast increasing incidence. In the vast majority of prostate cancer patients receiving hormone therapy, on average 18–36 months after the start of treatment refractoriness to androgen ablation develops.
S. Z. Safina, A. Z. Isyangulova
openaire +1 more source
Nature Communications, 2023 Neuroendocrine prostate cancer is a rapidly progressive and lethal disease characterized by early visceral metastasis, poor prognosis, and limited treatment options. Uncovering the oncogenic mechanisms could lead to the discovery of potential therapeutic
Yiyi Ji +20 more
doaj +1 more source
Genomic insights for neuroendocrine prostate cancer. [PDF]
J Chin Med AssocWang PH, Yang ST, Liu CH.
europepmc +3 more sources
Neuroendocrine Cancer of the Prostate
Pathology & Oncology Research, 2019 Neuroendocrine cancer of the prostate is considered to be a rare entity with bad prognosis and limited therapeutic options. We performed a prospective analysis of the patients treated in our hospital for prostate cancer between 1st January 2015 and 31rd December 2018. Neuroendocrine phenomena were tested by immunohistochemistry and laboratory chemistry
Noémi, Kránitz +3 more
openaire +2 more sources
MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer
Nature Communications, 2020 MUC1-C is overexpressed in castration-resistant prostate cancer and neuroendocrine prostate cancer. Here, the authors show that MUC1-C drives lineage plasticity through MYC and BRN2, inducing neuroendocrine features and stemness in prostate cancer.
Yota Yasumizu +22 more
doaj +1 more source
Cell Death and Disease, 2023 Current treatment options for prostate cancer focus on targeting androgen receptor (AR) signaling. Inhibiting effects of AR may activate neuroendocrine differentiation and lineage plasticity pathways, thereby promoting the development of neuroendocrine ...
Yu-Ching Wen +11 more
doaj +1 more source